David Shearer is a Dermatology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10060 Demia Way
The Dermatology Center
Florence, KY 41042
Telephone
859-525-6770Registry record last updated 16 Mar 2010.
Clinical trials
- Gentamicin Open Tibia Study
Sponsor: University of California, San Francisco
- Intramedullary Nailing Versus External Fixation in Open Tibia Fractures in Tanzania
Sponsor: University of California, San Francisco
- Pilot RCT Local Gentamicin for Open Tibial Fractures in Tanzania
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202520 payments
- Novartis Pharmaceuticals CorporationProgram year20253 payments
- Lilly USA, LLCProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
31.6%Azole Antifungal13.9%Ketoconazole100%Part D≥63 patientsTetracycline-class Drug8.3%Doxycycline Hyclate61%Minocycline Hcl39%Part D≥14 patients+ 2 more classes in this area
Dermatology
26.9%Corticosteroid16.5%Triamcinolone Acetonide65%Triamcinolone acetonide35%Part D + Part B≥41 patientsOther antifungals for topical use7.2%Ciclopirox100%Part D≥33 patients+ 2 more classes in this area
Sensory organs
25.7%Corticosteroid22.9%Betamethasone Valerate52%Clobetasol Propionate22%Alclometasone Dipropionate19%Betamethasone Dipropionate8%Part D<11 patientsAminoglycoside Antibacterial2.8%Gentamicin Sulfate100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”